Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CFO Richard Pulik sold 125,000 shares of Roivant Sciences stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $41.20, for a total value of $5,150,000.00. Following the completion of the sale, the chief financial officer owned 269,681 shares of the company's stock, valued at $11,110,857.20. The trade was a 31.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Richard Pulik also recently made the following trade(s):
- On Wednesday, November 11th, Richard Pulik sold 175,000 shares of Roivant Sciences stock. The stock was sold at an average price of $41.85, for a total value of $7,323,750.00.
Roivant Sciences Stock Performance
ROIV opened at $39.99 on Friday. The company's 50-day simple moving average is $37.20 and its two-hundred day simple moving average is $32.16. Roivant Sciences Ltd. has a 52-week low of $19.96 and a 52-week high of $42.50.
More Roivant Sciences News
These are some of the ROIV news items that stood out recently:
- Positive Sentiment: HC Wainwright raised its price target on ROIV, and recent analyst commentary has been bullish. A separate analysis points to pipeline momentum and potential contributions from trial results and drug-launch revenue. HC Wainwright price-target article Analyst commentary Pipeline momentum analysis
- Neutral Sentiment: A recent article discusses how clinical-trial outcomes and drug-launch revenue could affect Roivant’s stock, but the provided headline does not specify new trial results or revenue figures. Article on trial wins and launch revenue
- Negative Sentiment: CEO Eric Venker sold about 188,000 shares, reducing his position by 18.81%; the transaction was made under a pre-arranged Rule 10b5-1 plan. CFO Richard Pulik sold 125,000 shares on November 10 and another 175,000 on November 11, reducing his position by 44.08%. The sizable insider sales could pressure sentiment, though Venker’s sale was pre-scheduled. CEO SEC filing CFO SEC filing
Wall Street Analysts Forecast Growth
ROIV has been the topic of a number of research analyst reports. Guggenheim increased their price objective on shares of Roivant Sciences from $42.00 to $46.00 and gave the company a "buy" rating in a research report on Wednesday, September 9th. HC Wainwright lifted their target price on shares of Roivant Sciences from $47.00 to $48.00 and gave the stock a "buy" rating in a research report on Tuesday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Roivant Sciences in a research report on Wednesday, August 19th. Jefferies Financial Group boosted their target price on shares of Roivant Sciences from $42.00 to $52.00 and gave the company a "buy" rating in a research note on Tuesday, September 8th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Roivant Sciences in a report on Thursday, September 24th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $46.64.
Get Our Latest Report on Roivant Sciences
Institutional Investors Weigh In On Roivant Sciences
A number of large investors have recently made changes to their positions in the company. Wellington Management Group LLP increased its position in shares of Roivant Sciences by 179.0% during the 2nd quarter. Wellington Management Group LLP now owns 2,687,870 shares of the company's stock valued at $95,124,000 after purchasing an additional 1,724,588 shares during the last quarter. Maverick Capital Ltd. purchased a new position in shares of Roivant Sciences in the first quarter worth approximately $45,066,000. Assenagon Asset Management S.A. boosted its holdings in shares of Roivant Sciences by 18.2% in the second quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company's stock worth $295,965,000 after buying an additional 1,286,464 shares during the last quarter. Affinity Asset Advisors LLC boosted its holdings in shares of Roivant Sciences by 64.7% in the first quarter. Affinity Asset Advisors LLC now owns 2,800,000 shares of the company's stock worth $77,560,000 after buying an additional 1,100,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. bought a new stake in Roivant Sciences during the third quarter valued at approximately $35,624,000. 64.76% of the stock is currently owned by institutional investors.
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
